On the public citation graph

Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS‐CoV‐2 Infection and COVID‐19

https://doi.org/10.1002/cmdc.202200440

0 signed · 183 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2020.16349openalex-snapshot

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

inferredcites →https://doi.org/10.1002/anie.202016961openalex-snapshot

Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors

inferredcites →https://doi.org/10.1002/cmdc.202000223openalex-snapshot

Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics

inferredcites →https://doi.org/10.1007/s13238-021-00883-2openalex-snapshot

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332

inferredcites →https://doi.org/10.1016/j.amsu.2020.12.030openalex-snapshot

Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis

inferredcites →https://doi.org/10.1016/j.antiviral.2013.08.015openalex-snapshot

From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses

inferredcites →https://doi.org/10.1016/j.antiviral.2014.12.015openalex-snapshot

The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds

inferredcites →https://doi.org/10.1016/j.antiviral.2019.104541openalex-snapshot

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

inferredcites →https://doi.org/10.1016/j.antiviral.2021.105078openalex-snapshot

A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase

inferredcites →https://doi.org/10.1016/j.apsb.2020.08.014openalex-snapshot

Crystal structure of SARS-CoV-2 papain-like protease

inferredcites →https://doi.org/10.1016/j.apsb.2021.02.011openalex-snapshot

Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase

inferredcites →https://doi.org/10.1016/j.bmcl.2007.08.031openalex-snapshot

Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors

inferredcites →https://doi.org/10.1016/j.chembiol.2021.04.020openalex-snapshot

Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2

inferredcites →https://doi.org/10.1016/j.chempr.2020.04.023openalex-snapshot

Chemistry and Biology of SARS-CoV-2

inferredcites →https://doi.org/10.1016/j.clim.2020.108393openalex-snapshot

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

inferredcites →https://doi.org/10.1016/j.ejmech.2021.113584openalex-snapshot

Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies

inferredcites →https://doi.org/10.1016/j.ejmech.2022.114570openalex-snapshot

A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals

inferredcites →https://doi.org/10.1016/j.ejmech.2022.114596openalex-snapshot

A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals

inferredcites →https://doi.org/10.1016/j.ijantimicag.2020.105969openalex-snapshot

Drug repositioning is an alternative for the treatment of coronavirus COVID-19

inferredcites →https://doi.org/10.1016/j.tim.2016.09.001openalex-snapshot

Molecular Evolution of Human Coronavirus Genomes

inferredcites →https://doi.org/10.1016/j.virol.2004.11.038openalex-snapshot

Programmed ribosomal frameshifting in decoding the SARS-CoV genome

inferredcites →https://doi.org/10.1016/j.virol.2006.12.009openalex-snapshot

Membrane topology of murine coronavirus replicase nonstructural protein 3

inferredcites →https://doi.org/10.1016/j.virusres.2007.02.017openalex-snapshot

SARS coronavirus replicase proteins in pathogenesis

inferredcites →https://doi.org/10.1016/s0065-7743(06)41011-3openalex-snapshot

Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy

inferredcites →https://doi.org/10.1016/s0140-6736(15)60454-8openalex-snapshot

Middle East respiratory syndrome

inferredcites →https://doi.org/10.1016/s0140-6736(20)30183-5openalex-snapshot

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

inferredcites →https://doi.org/10.1016/s0140-6736(20)30304-4openalex-snapshot

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

inferredcites →https://doi.org/10.1016/s0731-7085(97)00102-7openalex-snapshot

Isolation and quantification of fluoroacetate in rat tissues, following dosing of Z-Phe-Ala-CH2-F, a peptidyl fluoromethyl ketone protease inhibitor

inferredcites →https://doi.org/10.1021/acs.jmedchem.0c01063openalex-snapshot

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19

inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00509openalex-snapshot

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00598openalex-snapshot

Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL pro )

inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00616openalex-snapshot

Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability

inferredcites →https://doi.org/10.1021/acs.jmedchem.1c01214openalex-snapshot

Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure–Activity Relationship, and X-ray Structural Studies

inferredcites →https://doi.org/10.1021/acs.jmedchem.1c01307openalex-snapshot

Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity

inferredcites →https://doi.org/10.1021/acs.jmedchem.2c00117openalex-snapshot

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

inferredcites →https://doi.org/10.1021/acs.jmedchem.2c00120openalex-snapshot

Potent Inhibition of SARS-CoV-2 nsp14 N 7-Methyltransferase by Sulfonamide-Based Bisubstrate Analogues

inferredcites →https://doi.org/10.1021/acs.jmedchem.2c00624openalex-snapshot

S-217622, a 3CL Protease Inhibitor and Clinical Candidate for SARS-CoV-2

inferredcites →https://doi.org/10.1021/acs.jmedchem.2c00636openalex-snapshot

Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination

inferredcites →https://doi.org/10.1021/acs.jmedchem.5b01461openalex-snapshot

An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy

inferredcites →https://doi.org/10.1021/acscatal.0c00110openalex-snapshot

Comprehensive Insights into the Catalytic Mechanism of Middle East Respiratory Syndrome 3C-Like Protease and Severe Acute Respiratory Syndrome 3C-Like Protease

inferredcites →https://doi.org/10.1021/acscentsci.0c00489openalex-snapshot

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

inferredcites →https://doi.org/10.1021/acscentsci.1c00039openalex-snapshot

Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV‑2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations

inferredcites →https://doi.org/10.1021/acsinfecdis.1c00023openalex-snapshot

Inhibitors of L-Type Calcium Channels Show Therapeutic Potential for Treating SARS-CoV-2 Infections by Preventing Virus Entry and Spread

inferredcites →https://doi.org/10.1021/acsinfecdis.1c00070openalex-snapshot

Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein–Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2

inferredcites →https://doi.org/10.1021/acsinfecdis.1c00131openalex-snapshot

The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors

inferredcites →https://doi.org/10.1021/acsmedchemlett.1c00140openalex-snapshot

Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate

inferredcites →https://doi.org/10.1021/acsmedchemlett.1c00263openalex-snapshot

Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein

inferredcites →https://doi.org/10.1021/acsmedchemlett.1c00299openalex-snapshot

Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors

inferredcites →https://doi.org/10.1021/acsptsci.1c00099openalex-snapshot

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir

inferredcites →https://doi.org/10.1021/bi00233a007openalex-snapshot

Peptidyl (acyloxy)methyl ketones and the quiescent affinity label concept: the departing group as a variable structural element in the design of inactivators of cysteine proteinases

inferredcites →https://doi.org/10.1021/ja00221a062openalex-snapshot

New inhibitors of cysteine proteinases. Peptidyl acyloxymethyl ketones and the quiescent nucleofuge strategy

inferredcites →https://doi.org/10.1021/jacs.1c08060openalex-snapshot

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity

inferredcites →https://doi.org/10.1021/jm0494873openalex-snapshot

Synthesis and Evaluation of Keto-Glutamine Analogues as Potent Inhibitors of Severe Acute Respiratory Syndrome 3CLpro

inferredcites →https://doi.org/10.1021/jm050548mopenalex-snapshot

Design and Synthesis of Peptidomimetic Severe Acute Respiratory Syndrome Chymotrypsin-like Protease Inhibitors

inferredcites →https://doi.org/10.1021/jm060173kopenalex-snapshot

Discovery of the HCV NS3/4A Protease Inhibitor (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key Steps in Structure-Based Optimization

inferredcites →https://doi.org/10.1021/jm301580nopenalex-snapshot

Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease

inferredcites →https://doi.org/10.1021/jm900611topenalex-snapshot

Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome−Coronavirus Papain-Like Protease

inferredcites →https://doi.org/10.1038/522139aopenalex-snapshot

South Korean MERS outbreak spotlights lack of research

inferredcites →https://doi.org/10.1038/nm1143openalex-snapshot

Severe acute respiratory syndrome

inferredcites →https://doi.org/10.1038/s41422-020-0356-zopenalex-snapshot

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

inferredcites →https://doi.org/10.1038/s41422-022-00618-wopenalex-snapshot

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

inferredcites →https://doi.org/10.1038/s41467-020-17495-9openalex-snapshot

Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin

inferredcites →https://doi.org/10.1038/s41467-020-18233-xopenalex-snapshot

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

inferredcites →https://doi.org/10.1038/s41467-020-18463-zopenalex-snapshot

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

inferredcites →https://doi.org/10.1038/s41467-020-20542-0openalex-snapshot

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

inferredcites →https://doi.org/10.1038/s41467-020-20718-8openalex-snapshot

The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery

inferredcites →https://doi.org/10.1038/s41467-021-20900-6openalex-snapshot

A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication

inferredcites →https://doi.org/10.1038/s41467-021-21060-3openalex-snapshot

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

inferredcites →https://doi.org/10.1038/s41467-021-23751-3openalex-snapshot

Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease

inferredcites →https://doi.org/10.1038/s41467-021-26760-4openalex-snapshot

Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets

inferredcites →https://doi.org/10.1038/s41467-022-29915-zopenalex-snapshot

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease

inferredcites →https://doi.org/10.1038/s41564-022-01119-7openalex-snapshot

An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron

inferredcites →https://doi.org/10.1038/s41577-021-00542-xopenalex-snapshot

Neutralizing monoclonal antibodies for treatment of COVID-19

inferredcites →https://doi.org/10.1038/s41579-018-0118-9openalex-snapshot

Origin and evolution of pathogenic coronaviruses

inferredcites →https://doi.org/10.1038/s41586-020-2008-3openalex-snapshot

A new coronavirus associated with human respiratory disease in China

inferredcites →https://doi.org/10.1038/s41586-020-2012-7openalex-snapshot

A pneumonia outbreak associated with a new coronavirus of probable bat origin

inferredcites →https://doi.org/10.1038/s41586-020-2601-5openalex-snapshot

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

inferredcites →https://doi.org/10.1038/s41594-021-00651-0openalex-snapshot

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis

inferredcites →https://doi.org/10.1038/s42003-020-01577-xopenalex-snapshot

Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents

inferredcites →https://doi.org/10.1039/d0md00367kopenalex-snapshot

Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics

inferredcites →https://doi.org/10.1056/nejmc2022236openalex-snapshot

Remdesivir for the Treatment of Covid-19 — Preliminary Report

inferredcites →https://doi.org/10.1056/nejmc2200591openalex-snapshot

Outpatient Remdesivir to Prevent Progression to Severe Covid-19

inferredcites →https://doi.org/10.1056/nejmoa030747openalex-snapshot

Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome

inferredcites →https://doi.org/10.1056/nejmoa2007016openalex-snapshot

Compassionate Use of Remdesivir for Patients with Severe Covid-19

inferredcites →https://doi.org/10.1056/nejmoa2007764openalex-snapshot

Remdesivir for the Treatment of Covid-19 — Final Report

inferredcites →https://doi.org/10.1056/nejmoa2015301openalex-snapshot

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

inferredcites →https://doi.org/10.1056/nejmoa2031994openalex-snapshot

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

inferredcites →https://doi.org/10.1056/nejmoa2116044openalex-snapshot

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

inferredcites →https://doi.org/10.1056/nejmoa2116846openalex-snapshot

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

inferredcites →https://doi.org/10.1056/nejmoa2118542openalex-snapshot

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

inferredcites →https://doi.org/10.1073/pnas.0510851103openalex-snapshot

Severe acute respiratory syndrome coronavirus papain-like protease: Structure of a viral deubiquitinating enzyme

inferredcites →https://doi.org/10.1073/pnas.0805240105openalex-snapshot

A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication

inferredcites →https://doi.org/10.1073/pnas.1835675100openalex-snapshot

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

inferredcites →https://doi.org/10.1073/pnas.2021946118openalex-snapshot

Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP

inferredcites →https://doi.org/10.1080/15376516.2017.1373882openalex-snapshot

The aminopeptidase inhibitor, z-L-CMK, is toxic and induces cell death in Jurkat T cells through oxidative stress

inferredcites →https://doi.org/10.1080/22221751.2022.2040341openalex-snapshot

Animal alphacoronaviruses found in human patients with acute respiratory illness in different countries.

inferredcites →https://doi.org/10.1086/420743openalex-snapshot

Severe Acute Respiratory Syndrome

inferredcites →https://doi.org/10.1093/cid/ciab456openalex-snapshot

Novel Canine Coronavirus Isolated from a Hospitalized Patient With Pneumonia in East Malaysia

inferredcites →https://doi.org/10.1093/nar/gkg916openalex-snapshot

Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design

inferredcites →https://doi.org/10.1093/ofid/ofab278openalex-snapshot

Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality

inferredcites →https://doi.org/10.1099/0022-1317-81-4-853openalex-snapshot

Virus-encoded proteinases and proteolytic processing in the Nidovirales

inferredcites →https://doi.org/10.1099/vir.0.19424-0openalex-snapshot

Mechanisms and enzymes involved in SARS coronavirus genome expression

inferredcites →https://doi.org/10.1111/bph.13895openalex-snapshot

Drug repurposing screens and synergistic drug‐combinations for infectious diseases

inferredcites →https://doi.org/10.1124/jpet.121.000688openalex-snapshot

Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development

inferredcites →https://doi.org/10.1126/science.abf1611openalex-snapshot

SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model

inferredcites →https://doi.org/10.1126/science.abl4784openalex-snapshot

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

inferredcites →https://doi.org/10.1126/scisignal.abe1202openalex-snapshot

High-resolution structures of the SARS-CoV-2 2′- O -methyltransferase reveal strategies for structure-based inhibitor design

inferredcites →https://doi.org/10.1126/scitranslmed.abl7430openalex-snapshot

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

inferredcites →https://doi.org/10.1128/aac.01652-20openalex-snapshot

Repurposing Nucleoside Analogs for Human Coronaviruses

inferredcites →https://doi.org/10.1128/aac.50.3.1013-1020.2006openalex-snapshot

SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells

inferredcites →https://doi.org/10.1128/jvi.01294-14openalex-snapshot

Catalytic Function and Substrate Specificity of the Papain-Like Protease Domain of nsp3 from the Middle East Respiratory Syndrome Coronavirus

inferredcites →https://doi.org/10.1128/jvi.01348-12openalex-snapshot

Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses

inferredcites →https://doi.org/10.1128/jvi.03688-14openalex-snapshot

Broad-Spectrum Inhibitors against 3C-Like Proteases of Feline Coronaviruses and Feline Caliciviruses

inferredcites →https://doi.org/10.1128/mbio.01423-21openalex-snapshot

Allosteric Activation of SARS-CoV-2 RNA-Dependent RNA Polymerase by Remdesivir Triphosphate and Other Phosphorylated Nucleotides

inferredcites →https://doi.org/10.1136/annrheumdis-2021-220049openalex-snapshot

Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals

inferredcites →https://doi.org/10.1136/bmj.n2697openalex-snapshot

Covid-19: UK becomes first country to authorise antiviral molnupiravir

inferredcites →https://doi.org/10.1177/1098612x17729626openalex-snapshot

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

inferredcites →https://doi.org/10.1186/1743-422x-10-359openalex-snapshot

In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East Respiratory Syndrome (MERS) Coronavirus infection

inferredcites →https://doi.org/10.1371/journal.ppat.1004113openalex-snapshot

Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating Activity of SARS-CoV Papain-Like Protease

inferredcites →https://doi.org/10.1586/14787210.5.2.245openalex-snapshot

Identification of new human coronaviruses

inferredcites →https://doi.org/10.21203/rs.3.rs-26344/v1openalex-snapshot

Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugs

inferredcites →https://doi.org/10.2174/138161206776361110openalex-snapshot

Antiviral Drug Discovery Targeting to Viral Proteases

inferredcites →https://doi.org/10.26434/chemrxiv.11728983.v1openalex-snapshot

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV

inferredcites →https://doi.org/10.26452/ijrps.v12i3.4798openalex-snapshot

In-Vitro CT-DNA Cleavage of Newly Synthesized Zn(II) Complex with P-Mercaptoaniline and Benzoate Ion

inferredcites →https://doi.org/10.32607/20758251-2016-8-4-23-32openalex-snapshot

Therapy of HIV Infection: Current Approaches and Prospects

inferredcites →https://doi.org/10.3389/fchem.2022.852210openalex-snapshot

Crystallization of Feline Coronavirus Mpro With GC376 Reveals Mechanism of Inhibition

inferredcites →https://doi.org/10.3390/cryst11050471openalex-snapshot

Virtual Screening and Molecular Docking Studies for Discovery of Potential RNA-Dependent RNA Polymerase Inhibitors

inferredcites →https://doi.org/10.3390/ijms17050678openalex-snapshot

SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6

inferredcites →https://doi.org/10.3390/ijms23010259openalex-snapshot

A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?

inferredcites →https://doi.org/10.3390/microorganisms9050893openalex-snapshot

Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase

inferredcites →https://doi.org/10.3390/molecules26195782openalex-snapshot

Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors

inferredcites →https://doi.org/10.3390/molecules26195795openalex-snapshot

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

inferredcites →https://doi.org/10.3390/molecules27092723openalex-snapshot

Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates

inferredcites →https://doi.org/10.3892/mmr.2020.11393openalex-snapshot

[Comment] The COVID‑19 pandemic as a scientific and social challenge in the 21st century

inferredcites →https://doi.org/10.4014/jmb.2110.10029openalex-snapshot

COVID-19 Drug Development

inferredcites →https://doi.org/10.47287/cen-09913-scicon3openalex-snapshot

Pfizer unveils its oral SARS-CoV-2 inhibitor

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.1002/9781394225156.ch1openalex-snapshot

Nirmatrelvir (Paxlovid with Ritonavir): A 3‐Chymotrypsin‐like Protease Inhibitor for Treating SARS‐CoV‐2 Infection

inferred← citeshttps://doi.org/10.1007/s11696-023-02804-5openalex-snapshot

Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs

inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.107380openalex-snapshot

Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review

inferred← citeshttps://doi.org/10.1016/j.bmc.2023.117316openalex-snapshot

Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety

inferred← citeshttps://doi.org/10.1016/j.bmc.2023.117498openalex-snapshot

Mass spectrometric assays monitoring the deubiquitinase activity of the SARS-CoV-2 papain-like protease inform on the basis of substrate selectivity and have utility for substrate identification

inferred← citeshttps://doi.org/10.1016/j.bmcl.2023.129489openalex-snapshot

SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads

inferred← citeshttps://doi.org/10.1016/j.drudis.2023.103579openalex-snapshot

COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease

inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115226openalex-snapshot

Korupensamine A, but not its atropisomer, korupensamine B, inhibits SARS-CoV-2 in vitro by targeting its main protease (Mpro)

inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115376openalex-snapshot

Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV)

inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115474openalex-snapshot

Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases

inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115667openalex-snapshot

Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors

inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115923openalex-snapshot

Targeting SARS-CoV-2 entry processes: The promising potential and future of host-targeted small-molecule inhibitors

inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116132openalex-snapshot

Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors

inferred← citeshttps://doi.org/10.1016/j.ijantimicag.2023.107039openalex-snapshot

Chrysin 7-O-β-D-glucuronide, a dual inhibitor of SARS-CoV-2 3CLpro and PLpro, for the prevention and treatment of COVID-19

inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2023.124772openalex-snapshot

Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 MPro and PLPro

inferred← citeshttps://doi.org/10.1016/j.omtn.2024.102331openalex-snapshot

Inhibition of SARS-CoV-2 growth in the lungs of mice by a peptide-conjugated morpholino oligomer targeting viral RNA

inferred← citeshttps://doi.org/10.1016/j.rechem.2025.102317openalex-snapshot

Role of structure-based drug design (SBDD) in the repurposing and discovery of anti-viral leads against Monkeypox virus disease

inferred← citeshttps://doi.org/10.1016/j.xpro.2023.102323openalex-snapshot

FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 Mpro and PLpro

inferred← citeshttps://doi.org/10.1021/acs.accounts.2c00735openalex-snapshot

SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies

inferred← citeshttps://doi.org/10.1021/acs.biochem.3c00075openalex-snapshot

Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants

inferred← citeshttps://doi.org/10.1021/acs.jafc.4c01942openalex-snapshot

Isolation, Virtual Screening, and Evaluation of Hazelnut-Derived Immunoactive Peptides for the Inhibition of SARS-CoV-2 Main Protease

inferred← citeshttps://doi.org/10.1021/acs.jced.3c00160openalex-snapshot

Solubility Measurement of the Crystal Form 1 and Form 4 Nirmatrelvir in Six Mono-Solvents and Two Binary Solvent Mixtures

inferred← citeshttps://doi.org/10.1021/acs.jcim.3c01518openalex-snapshot

On Inactivation of the Coronavirus Main Protease

inferred← citeshttps://doi.org/10.1021/acs.jcim.4c00334openalex-snapshot

Computational Insights into SARS-CoV-2 Main Protease Mutations and Nirmatrelvir Efficacy: The Effects of P132H and P132H-A173V

inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00818openalex-snapshot

Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group

inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c00384openalex-snapshot

New Strategies for Responding to SARS-CoV-2: The Present and Future of Dual-Target Drugs

inferred← citeshttps://doi.org/10.1021/acsmedchemlett.3c00417openalex-snapshot

Protease Inhibitors for Treating or Preventing Coronavirus Infection

inferred← citeshttps://doi.org/10.1021/acsptsci.2c00206openalex-snapshot

Broad-Spectrum Cyclopropane-Based Inhibitors of Coronavirus 3C-like Proteases: Biochemical, Structural, and Virological Studies

inferred← citeshttps://doi.org/10.1038/s41467-023-41312-8openalex-snapshot

Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets

inferred← citeshttps://doi.org/10.1038/s41467-025-56902-xopenalex-snapshot

Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates

inferred← citeshttps://doi.org/10.1038/s41467-025-59922-9openalex-snapshot

Identification of naturally occurring drug-resistant mutations of SARS-CoV-2 papain-like protease

inferred← citeshttps://doi.org/10.1039/d3md00056gopenalex-snapshot

Insights into targeting SARS-CoV-2: design, synthesis, in silico studies and antiviral evaluation of new dimethylxanthine derivatives

inferred← citeshttps://doi.org/10.1039/d3ob00653kopenalex-snapshot

Synthesis of optically active SARS-CoV-2 Mpro inhibitor drug nirmatrelvir (Paxlovid): an approved treatment of COVID-19

inferred← citeshttps://doi.org/10.1039/d6md00312eopenalex-snapshot

Design, synthesis, and X-ray structural studies of potent SARS-CoV-2 Mpro inhibitors containing tetrahydroisoquinoline-3-carboxamides as P2 ligands

inferred← citeshttps://doi.org/10.1080/07391102.2024.2304676openalex-snapshot

Identification of amentoflavone as a potent SARS-CoV-2 M pro inhibitor: a combination of computational studies and in vitro biological evaluation

inferred← citeshttps://doi.org/10.1126/science.adm9724openalex-snapshot

Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model

inferred← citeshttps://doi.org/10.1128/mbio.02878-23openalex-snapshot

Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment

inferred← citeshttps://doi.org/10.1248/bpb.b24-00369openalex-snapshot

Sunflower Trypsin Monocyclic Inhibitor Selected for the Main Protease of SARS-CoV-2 by Phage Display

inferred← citeshttps://doi.org/10.3389/fphar.2024.1452616openalex-snapshot

Potential of traditional medicines in alleviating COVID-19 symptoms

inferred← citeshttps://doi.org/10.3390/chemosensors11020135openalex-snapshot

Inhibitors of the RBD-ACE-2 Found among a Wide Range of Dyes by the Immunoassay Method

inferred← citeshttps://doi.org/10.3390/covid6030036openalex-snapshot

Broad-Spectrum Inhibitor Discovery Targeting Coronavirus Nucleocapsid Proteins via 3D Structure-Based Virtual Screening and Molecular Dynamics

inferred← citeshttps://doi.org/10.3390/ddc4040050openalex-snapshot

In Silico Evaluation of Structural Consequences in the Human CYP3A4 Caused by Molnupiravir-Induced Mutations During COVID-19 Treatment

inferred← citeshttps://doi.org/10.3390/ijms24054401openalex-snapshot

Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics

inferred← citeshttps://doi.org/10.3390/ijms25020971openalex-snapshot

Leveraging SARS-CoV-2 Main Protease (Mpro) for COVID-19 Mitigation with Selenium-Based Inhibitors

inferred← citeshttps://doi.org/10.3390/molecules28010303openalex-snapshot

Triterpenic Acid Amides as Potential Inhibitors of the SARS-CoV-2 Main Protease

inferred← citeshttps://doi.org/10.3390/pathogens13100825openalex-snapshot

Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors

inferred← citeshttps://doi.org/10.3390/v15010119openalex-snapshot

Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.